Centessa Pharmaceuticals PLC ADR (CNTA NASDAQ) stock market data APIs
$13.959
-0.14(-1%)
as of July 3, 2025
Try our APIs with
free plan!
Centessa Pharmaceuticals PLC ADR Financial Data Overview
Price chart is built with
Anychart
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Prev. Close
13.959
Open
13.8164
High
14.0909
Low
13.5843
52 wk Range
8.76-19.09
Market Cap
1 880 M
Shares Outstanding
134 M
Revenue
15 000 K
EPS
-0.2
Beta
1.488
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Centessa Pharmaceuticals PLC ADR data using free add-ons & libraries
Get Centessa Pharmaceuticals PLC ADR Fundamental Data
Centessa Pharmaceuticals PLC ADR Fundamental data includes:
- Net Revenue: 15 000 K
- EBITDA: -195 423 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Centessa Pharmaceuticals PLC ADR News
New
Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study
(RTTNews) - Nxera Pharma Co., Ltd. announced it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals under their research collaboration. The payments follow Centessa's initi...
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payme...
Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) Chief Business Officer Gregory M. Weinhoff sold 10,000 ordinary shares of the company on June 25, 2025, for a total of $138,642. The shares were sold at pric...
Centessa Pharmaceuticals' Accardi sells $210,000 in shares
Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold 15,000 ordinary shares of the company on June 24, 2025, for $14.00 each, totaling $210,000. The tra...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
